Stockscreener 앱 받기
5.80
3.81%
-0.23
시간 외 거래:
5.86
0.06
+1.03%
전일 마감가:
$6.03
열려 있는:
$5.61
하루 거래량:
1.75M
Relative Volume:
1.63
시가총액:
$925.52M
수익:
$53.61M
순이익/손실:
$-142.52M
주가수익비율:
-5.2252
EPS:
-1.11
순현금흐름:
$-141.83M
1주 성능:
-28.22%
1개월 성능:
-38.30%
6개월 성능:
-27.86%
1년 성능:
-1.86%
1일 변동 폭
$5.45
$6.23
1주일 범위
$5.45
$8.18
52주 변동 폭
$4.25
$16.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
명칭
Wave Life Sciences Ltd
전화
617-949-2900
주소
7 STRAITS VIEW, SINGAPORE
WVE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
5.80 | 925.52M | 53.61M | -142.52M | -141.83M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 32.85B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 28.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-25 | 개시 | Jefferies | Buy |
| 2024-10-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | 재개 | JP Morgan | Overweight |
| 2024-09-19 | 개시 | B. Riley Securities | Buy |
| 2024-09-09 | 개시 | JP Morgan | Overweight |
| 2024-05-15 | 개시 | Wells Fargo | Overweight |
| 2023-12-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Raymond James | Outperform |
| 2023-05-24 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-07-15 | 개시 | Cowen | Market Perform |
| 2019-04-17 | 재확인 | H.C. Wainwright | Buy |
| 2018-08-07 | 개시 | Stifel | Buy |
| 2018-07-23 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 재확인 | Mizuho | Buy |
| 2017-02-15 | 개시 | H.C. Wainwright | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-12-07 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-07 | 개시 | Jefferies | Buy |
| 2015-12-07 | 개시 | Leerink Partners | Outperform |
| 2015-12-07 | 개시 | Sun Trust Rbsn Humphrey | Buy |
모두보기
Wave Life Sciences Ltd 주식(WVE)의 최신 뉴스
(WVE) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 41% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - simplywall.st
RBC Cuts Price Target on Wave Life Sciences to $10 From $14, Keeps Sector Perform, Speculative Risk - MarketScreener
Wave Life Sciences’ SWOT analysis: RNA editing pioneer faces challenges in genetic medicine stock - Investing.com India
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance
What is Leerink Partnrs’ Estimate for WVE Q1 Earnings? - Defense World
Promising Genomics & Synthetic Biology Stocks to Consider in 2025 - Yahoo Finance
HC Wainwright Reaffirms “Buy” Rating for Wave Life Sciences (NASDAQ:WVE) - Defense World
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531 (NASDAQ:WVE) - Seeking Alpha
WAVE Life Sciences stock holds buy rating, $22 target from H.C. Wainwright - Investing.com Australia
Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531 - Yahoo Finance
Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar? - Nasdaq
Wave Life Sciences reports progress in DMD treatment By Investing.com - Investing.com Australia
Wave Aspires To Accelerated Approval In DMD With 48-Week Data - insights.citeline.com
Riding the Wave, exon skipper sails toward DMD filing - BioWorld Online
Sector Update: Health Care Stocks Retreat Wednesday Afternoon - MarketScreener
Jefferies maintains Buy on WAVE Life Sciences stock, $26 target By Investing.com - Investing.com South Africa
Wave Life Sciences to submit Duchenne drug for approval after Phase 2 success - The Boston Globe
Jefferies maintains Buy on WAVE Life Sciences stock, $26 target - Investing.com India
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year - Benzinga
Wave to seek FDA accelerated approval for Duchenne candidate in 2026 - MSN
Wave Life Sciences shares surge on positive DMD trial results By Investing.com - Investing.com Australia
Wave Life Sciences shares surge on positive DMD trial results - Investing.com
Wave Life Sciences reports progress in DMD treatment - Investing.com India
Wave Life Sciences Reports Positive Phase 2 Trial Results - TipRanks
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD - MarketScreener
Wave Life Sciences Announces Positive Data from FORWARD-53 - GlobeNewswire
Clinical Trial Breakthrough: New DMD Drug Achieves Unprecedented Muscle Recovery - StockTitan
Victory Capital Management Inc. Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Charles Schwab Investment Management Inc. Grows Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Wave Life Sciences director Christian Henry sells $102,574 in shares By Investing.com - Investing.com South Africa
Wave Life Sciences director Christian Henry sells $102,574 in shares - Investing.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Bank of New York Mellon Corp - Defense World
US Bancorp DE Cuts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Arizona State Retirement System Acquires 7,846 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
How To Trade (WVE) - Stock Traders Daily
Wave Life Sciences’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year - Investing.com
Mizuho maintains WAVE Life Sciences Outperform rating - Investing.com India
Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Paul Bolno Sells 169,025 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock - Defense World
HC Wainwright Cuts Earnings Estimates for Wave Life Sciences - Defense World
Wave Life Sciences CEO Paul Bolno sells shares worth $1.62 million - Investing.com UK
Wave Life Sciences (NASDAQ:WVE) Rating Increased to Hold at StockNews.com - Defense World
Q1 EPS Forecast for Wave Life Sciences Decreased by Analyst - Defense World
Commit To Purchase Wave Life Sciences At $7.50, Earn 25.6% Annualized Using Options - Nasdaq
Wave Life Sciences (NASDAQ:WVE) Earns “Buy” Rating from HC Wainwright - Defense World
Analysts Set Expectations for WVE Q1 Earnings - Defense World
H.C. Wainwright maintains $22 target on WAVE Life Sciences stock - Investing.com India
Wave Life Sciences’ Earnings Call Highlights Progress and Challenges - TipRanks
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2024 Earnings Call Transcript - MSN
Wave Life Sciences Ltd (WVE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Wave Life Sciences Ltd 주식 (WVE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HENRY CHRISTIAN O | Director |
Mar 20 '25 |
Sale |
9.77 |
10,500 |
102,574 |
16,115 |
0.48%
자본화:
|
볼륨(24시간):